Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Share-based Compensation (2016 - 2025)

Lipocine's Share-based Compensation history spans 13 years, with the latest figure at $53256.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 50.64% year-over-year to $53256.0; the TTM value through Sep 2025 reached $289058.0, down 37.46%, while the annual FY2024 figure was $409000.0, 37.46% down from the prior year.
  • Share-based Compensation reached $53256.0 in Q3 2025 per LPCN's latest filing, down from $65000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $178000.0 in Q1 2023 to a low of $53256.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $131187.5, with a median of $148000.0 recorded in 2021.
  • Peak YoY movement for Share-based Compensation: tumbled 68.54% in 2021, then rose 17.76% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $154946.0 in 2021, then increased by 6.6% to $165176.0 in 2022, then decreased by 7.37% to $153000.0 in 2023, then plummeted by 34.77% to $99800.0 in 2024, then tumbled by 46.64% to $53256.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Share-based Compensation are $53256.0 (Q3 2025), $65000.0 (Q2 2025), and $71002.0 (Q1 2025).